After reviewing new data on anemia drugs, the FDA included new warnings on the label: These drugs increase risk of heart attack and stroke.

FDA reviewed new data on anemia drugs, which included heightened risk of death and tumor growth in cancer patients who're taking these drugs for chemotherapy-induced anemia.

The FDA is again reviewing new data on anemia drugs, but previous warnings haven't stopped physicians from potentially over-prescribing dangerous anemia drugs and getting sizable rebates.

Here's one more reason for the FDA to review new data on anemia drugs: A Mayo Clinic study showed an increased risk of developing leukemia in patients with bone marrow disease.

Learn more about the causes, symptoms and treatment for anemia. The FDA is reviewing new data on the possible dangers of some anemia drugs, but there are other options available.

FDA is reviewing new data on a class of anemia drugs called erythropoietin, or ESA. Find out how these drugs work and why they could be dangerous.

Due to FDA's review of new data on the dangers of anemia drugs, the Centers for Medicare and Medicaid Services (CMS) established more stringent rules for coverage.

The bad news: The FDA has new data on the dangers of anemia drugs, and they don't reduce the need for blood transfusions. The good news: They could lower mortality in trauma patients.